Is ivonib a targeted drug? Detailed explanation of its mechanism of action and indications

Ivosidenib is indeed a targeted drug that is designed to treat cancer patients with specific molecular targets. Unlike traditional chemotherapy drugs, targeted drugs inhibit the growth and spread of tumors by interfering with specific molecular pathways of cancer cells, thereby reducing the impact on normal cells. Ivonib exerts its anti-cancer effect by targeting the specific molecular target of isocitrate dehydrogenase 1 (IDH1) mutation.

IDH1mutations are commonly found in certain types of cancer, such as acute myeloid leukemia (AML) and cholangiocarcinoma. Under normal circumstances, the IDH1 enzyme participates in the energy metabolism and redox reactions of cells, but after mutation, it catalyzes an abnormal metabolic product, leading to the proliferation of cancer cells. Ivonib inhibits the activity of this mutant enzyme and reduces the production of abnormal metabolites, thereby restoring normal cell differentiation and inhibiting tumor growth.

Avosidenib's targeting makes it an effective treatment option for cancers associated with IDH1 mutations. For patients with relapsed or refractory AML, ivosidenib provides a targeted treatment, especially when conventional chemotherapy is ineffective. In addition, ivonib also shows potential in the treatment of other tumors with IDH1 mutations, such as cholangiocarcinoma. Although these applications are still in clinical trials, they have shown some efficacy.

As a targeted drug, the side effects of ivonib are usually milder than those of traditional chemotherapy drugs. However, patient response needs to be closely monitored during treatment. Common side effects include fatigue, nausea, diarrhea and leukopenia, and more serious ones may include differentiation syndrome and cardiac QT interval prolongation. Therefore, patients should be under the guidance of a doctor when using ivonib to ensure the safety and effectiveness of the treatment.